Clinical Trial Update: Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid Arthritis [Phase 1]

View source ↗

Summary

A phase 1 safety study of a single dose REGN88 (SAR153191) in patients with rheumatoid arthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• REGN88 (SAR153191) (SAR153191)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Rheumatoid Arthritis | Phase 1 | Status: COMPLETED